
Carlsmed Inc (CARL) Stock Forecast & Price Target
Carlsmed Inc (CARL) Analyst Ratings
Bulls say
Carlsmed is a promising investment with a Buy rating and a projected price target of $17. Their AI platform for personalized spine fusions has resulted in lower revision rates and favorable reimbursement, which has led to increased surgeon adoption and revenue growth. While there are potential risks in the competitive market and operational and reimbursement challenges, the company has a strong patent portfolio, leadership team, and potential for further growth with their cervical platform and changes in the IPPS proposal.
Bears say
Carlsmed is currently unprofitable and there is a lack of transparency in terms of when cash flow breakeven can be reached. While the AI-enabled personalized solutions provided by the Aprevo technology platform may differentiate the company from traditional implants, the potential for pricing pressure and reimbursement changes could affect future revenue growth and dampen profitability. Additionally, the company's limited track record and reliance on a small customer base of surgeons may pose risks to its growth and market penetration potential.
This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.
Carlsmed Inc (CARL) Analyst Forecast & Price Prediction
Start investing in Carlsmed Inc (CARL)
Order type
Buy in
Order amount
Est. shares
0 shares